ESR1 and breast cancer: Among 240 women with stage 0–3 breast cancer, those assigned to a 10-week CBSM group intervention showed lower odds of mortality and recurrence at 8–15-year (11-year median) follow-up over and above the effect of age, time since surgery, stage, tumor receptor type (estrogen receptor/progesterone receptor), tumor size, and adjuvant therapy (Stagl et al. 2015b).